Upgrade to SI Premium - Free Trial

Neurocrine Bio. (NBIX) PT Lowered to $179 at BofA Securities

February 7, 2025 6:08 AM
BofA Securities analyst Tazeen Ahmad lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $179.00 (from $184.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles